CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors (CAP7-1)
Phase II Trial of CAP7.1 in Adult Patients With Refractory Malignancies: Small Cell Lung Carcinoma, Non-Small Cell Lung Carcinoma, Biliary Carcinoma (PIITCAP)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Charite, University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically- or cytologically-confirmed, advanced disease with documented progression (RECIST1.1.) after one or several chemotherapy line
- Patients may also have received molecular targeted therapy and progressed while on therapy or after completion
- Must have recovered from the acute reversible effects of previous anti-cancer chemotherapy, usually 3-4 weeks after myelosuppressive chemotherapy
Exclusion Criteria:
- Serious concurrent medical condition, which could affect compliance with the protocol or interpretation of results.
- Patients with uncontrolled infection and patients known to be infected with the human immunodeficiency virus (HIV) or hepatitis infection are not eligible for the study
- Pregnancy or breast-feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Small cell lung cancer
Histologically- or cytologically-confirmed, limited and extensive SCLC disease with progression after first or second line treatment
|
CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
|
|
EXPERIMENTAL: Non small cell lung cancer
Histologically- or cytologically-confirmed diagnosis of NSCLC with Stage IIIB or IV after failure of at least two lines of therapy
|
CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
|
|
EXPERIMENTAL: biliary tract cancer
Histologically or cytologically confirmed diagnosis of biliary tract cancer progress after first line therapy
|
CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to disease progression
Time Frame: 18 month
|
Assessment of antitumor activity based on RECIST 1.1 criteria (complete response; partial response; stable disease)
|
18 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
1. Percentage of Subjects With Objective Response [i.e., complete response (CR) + partial response (PR)] According to RECIST1.1
Time Frame: Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
|
Time to Treatment Failure
Time Frame: Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
|
Progression-Free Survival (PFS)
Time Frame: Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
|
Disease-free survival
Time Frame: Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
|
Overall Survival (OS)
Time Frame: Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
Time Frame: Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
|
Maximum Observed Drug Concentration (Cmax) of CAP7.1 in Plasma
Time Frame: Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
|
Time to Reach Maximum Drug Concentration (tmax) of CAP7.1 in Plasma
Time Frame: Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
|
Half-life Associated With the Terminal Slope (t1/2) of CAP7.1 in Plasma
Time Frame: Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
|
Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC) of CAP7.1 in Plasma
Time Frame: Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
Start of study treatment until 26 days post-last study treatment (approximately 4 years and 2 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CPN710102
- 2012-002378-30 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.